Cargando…
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
AIMS: To determine whether valsartan improves treadmill exercise time, in patients with symptomatic heart failure with a preserved ejection fraction (HFPEF), compared with placebo. METHODS AND RESULTS: In this multicentred, double-blind, 14-week study, patients were randomized to receive valsartan (...
Autores principales: | Parthasarathy, Hari K., Pieske, Burkert, Weisskopf, Marianne, Andrews, Chris D., Brunel, Patrick, Struthers, Allan D., MacDonald, Thomas M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754503/ https://www.ncbi.nlm.nih.gov/pubmed/19789402 http://dx.doi.org/10.1093/eurjhf/hfp120 |
Ejemplares similares
-
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021) -
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023) -
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016) -
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022) -
Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)